

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The company has five novel and differentiated drug development programs. OLINVYK[™] is approved by the FDA. Please see **Important Safety Information** including **Boxed Warning** in the full prescribing information available at OLINVYK.com. The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.

Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK[™] (oliceridine) injection in Pain and Therapy

Nov 20 2020, 7:00 AM EST

Trevena, Inc. to Participate in the Following November Virtual Investor Conferences

Nov 9 2020, 7:00 AM EST

Trevena, Inc. Announces DEA Scheduling of OLINVYK[™] (oliceridine) injection

Oct 30 2020, 7:44 AM EDT

Stock Overview

Symbol	TRVN
Exchange	Nasdaq
Market Cap	370.59m
Last Price	\$2.36
52-Week Range	\$0.46 - \$3.68

12/04/2020 04:00 PM EST

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
Managing Director
T: 617-430-7576
daniel@lifesciadvisors.com

Management Team

Carrie L. Bourdow

President and Chief Executive Officer

Scott Applebaum

Chief Legal and Compliance Officer, SVP of Regulatory Affairs and Corporate Secretary

Mark A. Demitrack, MD

Senior Vice President, Chief Medical Officer

Barry Shin

Senior Vice President, Chief Financial Officer

Robert T. Yoder

Senior Vice President, Chief Commercial Officer

Joel S. Solomon, Esq.

Vice President, Legal & Compliance

Linda Wase, MD

Vice President, Clinical Operations and Medical Affairs

Michael S. Kramer

Vice President, Scientific Operations & Alliance Management

Katrine Sutton

Vice President, Finance Planning & Analysis

Michael J. Fossler, Pharm. D., Ph. D., F.C.P.

Vice President, Clinical Development and Quantitative Sciences

Trevena, Inc.

955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.